Drug interaction between clopidogrel and proton pump inhibitors

Pharmacotherapy

Volumn 30, Issue 3, 2010, Pages 275-289

  Liu, Tina J ^a,b   Jackevicius, Cynthia A ^a,b,c,d,e  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c TORONTO GENERAL HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

Clopidogrel; Drug drug interaction; Omeprazole; PPI; Proton pump inhibitor; Thienopyridine

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PRASUGREL; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ACUTE HEART INFARCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA BASE; DEATH; DRUG ANTAGONISM; DRUG ELIMINATION; DRUG METABOLISM; GASTROINTESTINAL HEMORRHAGE; HOSPITAL READMISSION; HUMAN; LOADING DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; STROKE; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

ASPIRIN; BIOLOGICAL MARKERS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEART; HUMANS; METABOLIC DETOXICATION, PHASE I; PLATELET AGGREGATION INHIBITORS; PRODRUGS; PROTON PUMP INHIBITORS; TICLOPIDINE;

EID: 77649223721     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.3.275     Document Type: Review

References (67)

1. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-elevation. N Engl J Med 2001;345:494-502.
2. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20.
3. Aronow HD, Steinhubl SR, Brennan DM, Berger PB, Topol EJ. Bleeding risk associated with 1-year dual antiplatelet therapy after percutaneous intervention: insights from the clopidogrel for the reduction of events during observation (CREDO) trial. Am Heart J 2009;157:369-74.
4. Schreiner GC, Laine L, Murphy SA, Cannon CP. Evaluation of proton pump inhibitor use in patients with acute coronary syndromes based on risk factors for gastrointestinal bleed. Crit Pathways in Cardiol 2007;6:169-72.
5. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation task force on clinical expert consensus documents. Circulation 2008;118:1894-909.
6. Bristol-Myers Squibb-sanofi-aventis. Plavix (clopidogrel) package insert. Bridgewater, NJ; 2008.
7. Oqueli E, Hiscock M, Dick R. Clopidogrel resistance. Heart Lung Circ 2007;16:S17-28.
8. Nguyen T, Frishman WH, Nawarskas J, Lerner RG. Variability of response to clopidogrel: possible mechanisms and clinical implications. Cardiol Rev 2006;14:136-42.
9. Horn JR, Hanstem PD. Clopidogrel: some drugs may reduce its effectiveness [drug interactions]. Pharm Times 200;4:33.
10. Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 2006;29:769-84.
11. Stedman CAM, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000;12:963-78.
12. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004;109:166-71.
13. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-62.
14. Desai NR, Mega JL, Jiang S, Cannon CP, Sabatine MS. Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 2009;53:1273-8.
15. Bliden KP, Dichiara J, Lawal L, et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol 2008;52:531-3.
16. Yousef AM, Arafat T, Bulatova NR, Al-Zumyli R. Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel. J Clin Pharm Ther 2008;33:439-49.
17. Addad F, Chakroune T, Asma A, et al. Clopidogrel but not aspirin prevents acute smoking-induced platelet aggregation in patients with stable coronary artery disease. Thromb Res 2009;123:640-3.
18. Patrono C, Bachmann F, Baigent C, et al. Expert consensus document on the use of antiplatelet agents: the task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur Heart J 2004;25:166-81.
19. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;108:921-4.
20. Müller I, Besta F, Schulz C, Massberg S, Schönig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003;89:783-7.
21. Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 2006;29:769-84.
22. Stedman CAM, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000;12:963-78.
23. Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004;32:821-7.
24. Gilard M, Arnaud B, Cornily J-C, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. J Am Coll Cardiol 2008;51:256-60.
25. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008;48:475-84.
26. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009;157:148.e1-5.
27. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009;101:714-19.
28. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton pump inhibitor: an analysis of two randomized trials. Lancet 2009;374:989-97.
29. Pezalla E, Day D, Pullliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors [letter]. J Am Coll Cardiol 2008;52:1038-9.
30. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713-18.
31. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-44.
32. Auber RE, Epstein RS, Teagarden JR, et al. Proton pump inhibitors effect on clopidogrel effectiveness: the clopidogrel Medco outcomes study [abstract 3998]. Circulation 2008;118:S815.
33. Dunn SP, Macaulay TE, Brennan DM, et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial [abstract 3999]. Circulation 2008;118:S815.
34. Stanek EJ, Aubert RE, Flockhart FA, et al. A national study of the effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopidogrel following coronary stenting: the clopidogrel Medco outcomes study. Presented at the meeting of the society of cardiovascular angiography and interventions, Las Vegas, Nevada, May 6-9, 2009.
35. Bhatt DL, Cryer B, Contant CF, et al. Clopidogrel and the optimization of GI events trial (COGENT). Presented at the transcatheter cardiovascular therapeutics meeting, San Francisco, California, September 21-25, 2009.
36. Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003;59:295-302.
37. Mueller T, Dieplinger B, Poelz W, Calatzis A, Haltmayer M. Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel multiplate analyzer-comparison with two flow cytometric methods. Thromb Res 2007;121:249-58.
38. Muller-Schunk S, Linn J, Peters N, et al. Monitoring of clopidogrel-related platelet inhibition: correlation of nonresponse with clinical outcome in supra-aortic stenting. AJNR Am J Neuroradiol 2008;29:786-91.
39. Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007;50:1822-34.
40. Holubarsch C, Schneider R, Pieske B, et al. Positive and negative inotropic effects of DL-sotalol and D-sotalol in failing and nonfailing human myocardium under physiological experimental conditions. Circulation 1995;92:2904-10.
41. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidencebased clinical practice guidelines. Chest 2008;133:160-98.
42. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007;102:507-15.
43. Chin MW, Yong G, Bulsara MK, Rankin J, Forbes GM. Predictive and protective factors associated with upper gastrointestinal bleeding after percutaneous intervention: a case control study. Am J Gastroenterol 2003;38:693-700.
44. Ma L, Elliott SN, Cirino G, Buret A, Ignarro LJ, Wallace JL. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci U.S.A. 2001;98:6470-5.
45. Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study [online exclusive article]. BMJ 2006;333:726. Available from http://www.bmj.com/cgi/content/full/333/7571/726? view=long&pmid=16984924.
46. Chan FKL, Ching JYL, Hung LCT, et al. Clopidogrel vs aspirin plus esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005;352:238-44.
47. Griffin MR, Ray WA, Schaffner W. Nonsteroidal antiinflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988;109:359-63.
48. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991;114:257-63.
49. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal antiinflammatory drugs. Ann Intern Med 1991;114:735-40.
50. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993;153:1665-70.
51. Carson JL, Strom BL, Morse ML, et al. The relative gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. Arch Intern Med 1989;149:1019-22.
52. Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991;91:213-22.
53. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9.
54. Trifiro G, Corrao S, Alacqua M, et al. Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources. Br J Clin Pharmacol 2006;62:582-90.
55. Wohlt PD, Hansen LA, Fish JT. Inappropriate continuation of stress ulcer prophylactic therapy after discharge. Ann Pharmacother 2007;41:1611-16.
56. U.S. Food and Drug Administration. Bulletin: early communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix), January 2009. Available from http://www.fda.gov/cder/drug/early-comm/ clopidogrel-bisulfate.htm. Accessed April 21, 2009.
57. Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther 1999;13(suppl 3):18-26.
58. Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: international guidelines on management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:1-33.
59. Hiltz SW, Black E, Land G, et al. American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology 2008;135:1383-91.
60. Koch M, Dezi A, Ferrario F, et al. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. Arch Intern Med 1996;156:2321-32.
61. Taha AS, Hudson N, Hawkey DM, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996;334:1235-9.
62. French PC, Darekar BS, Mills JG, et al. Ranitidine in the prevention of nonsteroidal anti-inflammatory drug-associated gastric and duodenal ulceration in arthritic patients. Eur J Gastroenterol Hepatol 1994;6:1141-7.
63. TheHeart.org by WebMD. COGENT-1 trial scrapped, sponsor declares bankruptcy, January 2009. Available from http://www.theheart.org/article/936651. do. Accessed March 9, 2009.
64. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-75.
65. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-62.
66. Abuzahra M, Pillai M, Caldera A, et al. Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug-eluting stents. Am J Cardiol 2008;102:401-3.
67. Lemesle G, Delhaye C, Sudre A, et al. Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome. Am Heart J 2009;157:375-82.